BeaMed is a pioneering brand that is revolutionizing guided laser surgery, particularly in the fields of tumor ablation and epilepsy treatments. With their cutting-edge technology, BeaMed is developing a unique range of light-based surgical tools and systems that will elevate the standards of minimally invasive treatments. At the core of BeaMed's technology is the ability to reshape deposited laser energy in real-time, ensuring a precise match with the targeted area, all while utilizing advanced imaging modalities for verification.

BeaMed's flagship product, the StingRay Laser System, is a groundbreaking thermal ablation technology that enables new treatment options for oncology procedures, including brain, prostate, liver, breast, and lung cancers. Additionally, the StingRay System opens doors for previously inoperable epilepsy cases. BeaMed's proprietary technologies, including DiLITT, ExLITT, and APM, provide exceptional control over laser energy, minimizing risks and optimizing clinical outcomes.

By offering advanced solutions for brain tumors and drug-resistant epilepsy, as well as providing less invasive therapeutic options for lung cancer and prostate cancer, BeaMed is transforming the landscape of surgical treatments. Leading the BeaMed team is CEO Gil Shapira, a renowned expert in surgical lasers, and CTO Moshe Eshkol, a solid-state physicist with a wealth of experience in medical innovations. With their ISO13485:2016 certification and headquarters in Caesarea Industrial Park, Israel, BeaMed is making strides towards improving patients' lives worldwide